Company intelligence / Profile preview

Lin Bioscience International

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Lin BioScience is a Taiwan-based, clinical-stage biopharmaceutical drug development company (TPEx: 6696) focused on first-in-class small-molecule therapies in ophthalmology, oncology and metabolic disease; its subsidiary Belite Bio is running phase 3 trials of RBP4 inhibitor tinlarebant (LBS-008) for Stargardt disease and geographic atrophy, while Lin BioScience is conducting phase 1/2 trials of CDC7 inhibitor LBS-007 in relapsed/refractory acute leukemias and developing glioblastoma/brain metastasis candidate LBS-002 and NASH/type 2 diabetes candidate LBS-009.[1][2][3][4][6]

Therapeutic areas: HematologyEndocrinologyGastroenterologyOncologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Lin Bioscience International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lin Bioscience International.

Explore the full profile